About LB Pharmaceuticals Inc Common Stock
https://lbpharma.usClinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.
CEO
Heather D. Turner
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 32
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
TCG CROSSOVER MANAGEMENT, LLC
Shares:1.75M
Value:$33.78M
JENNISON ASSOCIATES LLC
Shares:739.04K
Value:$14.31M
ALYESKA INVESTMENT GROUP, L.P.
Shares:675K
Value:$13.07M
Summary
Showing Top 3 of 6
About LB Pharmaceuticals Inc Common Stock
https://lbpharma.usClinical‑stage biopharmaceutical company developing novel therapies for neuropsychiatric diseases (e.g. schizophrenia, bipolar depression). Lead candidate is LB‑102, a methylated derivative of amisulpride.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $5.17M ▼ | $-3.56M ▲ | 0% | $-0.14 ▲ | $-3.48M ▲ |
| Q3-2024 | $0 | $16.08M ▼ | $-14.18M ▲ | 0% | $-0.63 ▲ | $-14.18M ▲ |
| Q2-2024 | $0 | $26.58M ▲ | $-27.7M ▼ | 0% | $-7.82 ▼ | $-27.05M ▼ |
| Q1-2024 | $0 | $16.63M | $-16.15M | 0% | $-4.56 | $-16.15M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $314.48M ▲ | $320.75M ▲ | $10.53M ▼ | $310.22M ▲ |
| Q2-2025 | $14.22M ▼ | $19.25M ▼ | $123.12M ▼ | $-103.87M ▼ |
| Q1-2024 | $72.13M | $74.26M | $124.71M | $-50.45M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2024 | $-14.18M ▲ | $-22.04M ▼ | $28.87M ▲ | $20K ▲ | $0 ▲ | $-22.48M ▼ |
| Q2-2024 | $-27.7M ▼ | $-15.78M ▼ | $6.89M ▲ | $3K ▼ | $-8.89M ▼ | $-15.82M ▼ |
| Q1-2024 | $-16.15M | $-9.57M | $-26.06M | $38.29M | $2.65M | $-9.62M |
CEO
Heather D. Turner
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 32
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
TCG CROSSOVER MANAGEMENT, LLC
Shares:1.75M
Value:$33.78M
JENNISON ASSOCIATES LLC
Shares:739.04K
Value:$14.31M
ALYESKA INVESTMENT GROUP, L.P.
Shares:675K
Value:$13.07M
Summary
Showing Top 3 of 6